Objective: To observe the effect of liraglutide combined with human umbilical cord mesenchymal stem cells on type 2 diabetes mellitus with nonalcoholic fatty liver disease rats liver injury. And then to investigate relation of the effect on the liver injury between the toll-like receptor 4/nuclear factor-kappa B inflammatory signal pathway and oxidative stress mechanism.

Methods: Animal model establishment and experimental grouping and intervention: The rats were randomly selected and divided into the following four groups: T2DM with NAFLD model group, hUC-MSCs treatment group, Liraglutide treatment group, Liraglutide combined with hUC-MSCs treatment group.

Results: 1. Rat serum levels of TNF-α, IL-6, 8-OHdG and SOD: Compared with MC+LIRA group, the levels of TNF-α, IL-6 and 8-OHdG were decreased in MC+LIRA+hUC-MSCs group (P <0.05), SOD was increased (P<0.05). 2. Pathological changes of rats liver tissue:Compared with MC+LIRA group, the NAS score were decreased in MC+LIRA+hUC-MSCs group (P <0.05).3. Expression of TLR4 and NF-κB mRNA in rat liver tissue: Compared with MC+hUC-MSCs group, the expression of TLR4 and NF-κB mRNA were significantly decreased in MC+LIRA group and MC+LIRA+hUC-MSCs group (P<0.05). Compared with MC+LIRA group, the expression of TLR4 and NF-κB mRNA were decreased in MC+LIRA+hUC-MSCs group (P <0.05).

Conclusion: The mechanism of liraglutide combined with human umbilical cord mesenchymal stem cells on type 2 diabetes mellitus with nonalcoholic fatty liver disease is closely related to the down-regulation of TLR4/NF-κB inflammation pathway and oxidative stress.

Disclosure

P. Chen: None.

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.